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Abstract. Small cell lung cancer is the most aggressive lung 
cancer subtype. The standard treatment approach is based on 
cisplatin regimens. Although response rates to treatment are 
approximately 60-80%, the median survival is still very poor. 
Excision repair cross complementation group 1 (ERCC1)  is an 
enzyme that removes cisplatin-induced DNA adducts and has 
been related with prognosis and cisplatin response. Topotecan 
is the standard treatment as second-line therapy and it is an 
inhibitor of topoisomerase I (TOP I). We selected 76 patients 
with small cell lung (SCLC) to analyze the ERCC1 and TOP 
I mRNA expression. ERCC1 was studied both by quantitative 
PCR and immunohistochemistry. A significant association 
was found between the inmunohistochemistry expression of 
ERCC1 and the lack of platinum response (p=0.001). Moreover, 
low levels of TOP I RNA were shown to be linked to cisplatin 
response (p=0.002). In the survival analysis, a significant corre-
lation between a better PFS with a low TOP I RNA expression 
as well as a negative ERCC1 inmunostaining were found, in both 
cases with a significant p-value (p=0.02 and 0.009, respectively). 
In summary, our results suggest the use of ERCC1 immuno-
histochemistry and TOP I mRNA analysis to predict cisplatin 
response and prognosis in SCLC patients.
Introduction
Small cell lung cancer (SCLC) is the most aggressive lung 
cancer subtype, with a strong tendency for early dissemination 
as well as high frequency of metastasis. SCLC accounts for 14% 
of new lung cancer cases diagnosed in USA and Europe (1) 
and staging determines prognosis and treatment. The standard 
treatment approach to patients with limited stage (SCLC) and 
good performance status is a combination of chest radiation 
and chemotherapy based on cisplatin (P) and etoposide (E), 
which results in complete response rate of 50-80% and a 5-year 
survival probability of 12-25% (2). In case of extensive disease 
(ED), the main treatment is a combination of cisplatin with 
either etoposide or irinotecan. Reponses rates are approximately 
60-80% and the median survival reaches 7-12 months.
Cisplatin causes monoadducts and intrastrand or inter-
strand cross-links in DNA (3,4). Nucleotide excision repair 
plays a central role among DNA repair pathways and has been 
associated with resistance to cisplatin-based chemotherapy. 
The excision repair cross complementation group 1 (ERCC1) 
enzyme, plays a rate-limiting role in the nucleotide excision 
repair pathway which recognizes and removes cisplatin-
induced DNA adducts (5). The role of ERCC1 in resolving 
DNA interstrand cross-link-induced double-strand breaks 
has been clearly shown (6-8). Various studies have reported 
the relationship between ERCC1 expression and the effect 
of cisplatin-induced DNA adducts in human ovarian cancer 
cells in vitro (9), in primary gastric adenocarcinomas (10), 
colorectal cancer (11) and, more recently, in esophageal 
cancer (12). Pivotal data from primary non-small cell lung 
cancer (NSCLC) specimens have suggested a link between 
ERCC1 immunoexpression and cisplatin resistance. However, 
for NSCLC untreated patients, a high ERCC1 expression in 
selected cases was associated with a better survival (13,14). 
Taken together, all these studies show that ERCC1 expression 
level could be inversely associated with cisplatin response. 
However in terms of prognosis, high levels of ERCC1 expres-
sion are a favourable prognostic factor of survival in some 
tumors like NSCLC. Nevertheless, the value of ERCC1 as 
cisplatin predictor and as prognosis marker in SCLC has 
scarcely been explored with only two previous studies showing 
contradictory results (15,16).
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Topotecan and irinotecan are topoisomerase I (TOP I) 
inhibitors that are active in the treatment of chemotherapy-
naive and chemotherapy-sensitive patients with recurrent 
SCLC. Topoisomerases are enzymes capable of altering DNA 
topography for the purposes of relieving torsional strain during 
processes like replication, transcription, and recombination. 
These enzymes facilitate passing one strand of DNA through 
a break in the opposing strand (type I subfamily) or passing a 
duplex from the same or different molecule through a double 
stranded gap (type II subfamily). Topoisomerases can relax 
either negative supercoils, or both positive and negative super-
coils of the DNA. These unique features are needed because 
of the double helical structure of DNA, in which TOPOs help 
access stored information for transcription, recombination and 
replication purposes (17).
Topotecan (T) is the standard treatment as second-line 
setting for patients with chemotherapy-sensitive disease (durable 
response to first line therapy of at least 3 months), with response 
rate of 19-37%. In addition, topotecan has been studied as doublet 
and triplet combination regimens to help assess its potential in 
first-line treatment of SCLC. Topotecan has shown preliminary 
results of 75% of objective responses in combination with pacli-
taxel (18), 90% with paclitaxel and carboplatin, (19) 81% with 
etoposide and carboplatin, (20) and 67% with ifosfamide (21). 
Although TOP I inhibitors have attracted extensive interest in 
the treatment of SCLC, there are no studies analyzing the role 
of changes in TOP I expression in this tumor.
Resistance to chemotherapy is the main cause of poor 
outcome in patients with SCLC (22). Therefore, the identification 
of markers that may identify those patients who would benefit 
from the current chemotherapy or chemoradiotherapy (CRT) 
approaches has strong clinical implications. To this aim, we 
retrospectively analyzed the ERCC1 and TOPO I expression as 
predictors of response and survival in a SCLC patients cohort 
treated with platinum-based combination chemotherapy.
Patients and methods
Patients and samples. Between January 2000 and December 
2007, 228 patients were diagnosed with SCLC. Of these clinico-
pathological data and adequate tissue were available in 76 
(33.3%) patients; therefore, this group was selected for the study. 
All patients were treatment naive. Tissue samples were taken 
from their primary tumor by bronchoscopic or thoracoscopic 
biopsy in 73 cases and from the metastatic sites (bone marrow) in 
three patients. The Veterans Administration Lung Study Group 
system was used for staging patients (22).
The most commonly administered chemotherapy regimen 
was EP in 53 cases (etoposide 100 mg/m2, cisplatin 25 mg/m2 
on days 1-3; 50 patients), followed by carboplatin-etoposide 
in 22 patients (carboplatin AUC 5 y 6 etoposide on day 1 
and etoposide 100 mg/m2, on days 1-3). Chemotherapy was 
repeated every 3 weeks. Among all the patients who underwent 
chemotherapy, 19 received 4 cycles and 54 patients received 
6 cycles of an etoposide-platinum combination. In patients 
with ED SCLC, two to four additional cycles of chemotherapy 
were administered if a response was achieved after two cycles 
of chemotherapy. Thoracic concurrent irradiation (45 Gy) was 
performed in patients with limited disease and it was started 
with the second-third courses of chemotherapy on the same day. 
Among second line chemotherapy regimens, the most common 
treatment used was CAV (cisplatin, adriamycin and vincristine) 
in 31.5% followed by paclitaxel (21%) and topotecan (10%). 
Fifteen patients received chemotherapy and the most common 
regimen administered was topotecan (11.8% of all the patients 
included) (Table I).
Response to treatment was evaluated with chest CT after 
the third and sixth course of chemotherapy in ED SCLC, and 
after the concurrent chemo-radiation treatment in limited stage 
(LD), according to the World Health Organization criteria (23). 
Patients were defined platinum-resistant when time to progres-
sion after EP was less than 3 months. After the completion of 
treatment, patients were evaluated with chest CT every 3 months 
for the first and second year, every 6 months for the next 3 years, 
and yearly thereafter.
ERCC1 immunohistochemistry. Bronchoscopic lung biopsies 
were fixed in 4% buffered formaldehyde and embedded in 
paraffin (FFPE). Four-micrometer-thick sections were cut and 
stained with hematoxylin and eosin for pathological review. 
The study was approved by the institutional review board of 
the hospital. Gene expression analysis was performed blinded 
to the clinico-pathological data.
Sections of 4 µm were cut from formalin-fixed, paraffin-
embedded tissue blocks from the afore-mentioned patients. 
Slides were de-paraffined and endogenous peroxidase activity 
was blocked by incubation in 3% H2O2 in methanol for 10 min 
at room temperature (RT). Antigens were retrieved by incu-
bation in EDTA for 45 min at 155oC. The primary mouse 
anti-human monoclonal antibodies against ERCC1 (ERCC1 
Ab-2, Neomarkers, Fremont, CA, USA) was diluted at 1:100 
in 1% BSA in TBS. Tissue slides were incubated with the 
antibody for 30 min at RT. Slides were then rinsed in TBS and 
incubated with the peroxidase-based EnVision™ kit (Dako 
Corp., Carpinteria, CA, USA) for 30 min at RT. Afterwards, 
specimens were incubated with diaminobenzidine chromo-
genic substrate (Dako Corp.) for 5 min at RT. Sections were 
counterstained with hematoxylin, stepwise dehydrated through 
graded alcohols and cleared in xylene.
Immunohistochemical score. The negative controls for these 
proteins were made by omission of the primary antibody during 
the process of immunohistochemical staining. The positive 
controls for ERCC1 were the presence of staining in the non-tumor 
bronchial mucosa. The slides were examined independently by 
two expert surgical pathologists blinded to both clinical and 
pathologic data. Discordant results were discussed and agreed on 
by both pathologists. Immunohistochemical staining was quanti-
fied using a visual grading system based on the extent of staining 
(percentage of positive tumor cells) according to the grading 
system of Soria et al. It was considered positive when more than 
10% of the cells showed nuclear staining (24).
ERCC1 and TOP I quantitative PCR. RNA isolation was 
performed from the formalin-fixed paraffin-embedded broncho-
scopic lung biopsies. Ten (5 µm) sections from each endoscopic 
specimen block were placed into a microcentrifuge tubes. 
One additional 4-µm section was stained with hematoxylin 
and eosin (H&E). Paraffin was removed by xylene extraction, 
and RNA was isolated using a commercially available kit: 
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Epicentre Technologies Inc. (Madison, WI), MasterPure RNA 
Purification kit according to the manufacturer's instructions. 
Total RNA was measured spectrophotometrically, measure-
ments were performed in UltraPure destillated water DNAse, 
RNAse free (Gibco, Invitrogen). Reverse transcription of RNA 
derived from FFPE material was performed from 250 ng of 
total RNA of each case and 125 U Multiscribe reverse transcrip-
tase (High-Capacity cDNA Archive Kit, Applied Biosystems, 
Foster City, CA, USA). Random primers were used to primer 
cDNA synthesis. Relative cDNA quantitation for both ERCC1 
and TOPO 1 against the reference gene (β-actin) was done 
using a fluorescence-based real-time detection method [ABI 
PRISM 7900 Sequence Detection System (TaqMan); Applied 
Biosystems]. We profiled expression of the three genes ERCC1 
(Hs Hs01012158_m1 assay), TOP I (Hs01052825_m1) and the 
internal reference ACTH (Hs99999903m1 assay) (in triplicates). 
These TaqMan primers and probes are designed to produce 
amplicons of around 100 nucleotides. ERCC1 and TOP I Gene 
expression levels are expressed as ratios (differences between 
the Ct values) between two absolute measurements (genes of 
interest/internal reference gene).
Statistical analysis. Overall survival (OS) and progression-free 
survival (PFS) was calculated using the Kaplan-Meier method. 
The differences between the survival curves were tested by 
using the log-rank test.
The Cox proportional-hazards regression model was used 
to determine the joint effects of several variables on survival. A 
comparison of clinico-pathological characteristics was evaluated 
with Fisher's exact test. Cox's proportional hazards multivariate 
analysis was used to evaluate which of the significant factors at 
the univariate analysis had a significant influence on survival. 
Statistical significance was set at p=0.05. All analyses were 
performed with SPSS for Windows 13.0 software.
Results
Patient characteristics. The clinico-pathological characteristics 
of the 76 patients are listed in Table I. Of the patients 49 (65%) 
had an ED whereas 27 (35%) had LD. All received chemo-
therapy based on PE with concurrent radiation in LD. Among 
the 76 patients selected, 43 (51.3%) were considered platinum 
responders and 33 (48.7%) platinum resistant, according to the 
definition previously given.
ERCC1 expression and cisplatin response. Positive immuno-
expression of ERCC1 was observed in 29 (52%) whereas in 
24 patients the ERCC1 immunostaining was negative (45.3%) 
(positive immunostaining of ERCC1; Fig. 1). Twenty-six cases 
could not be evaluated for the immunohistochemistry and PCR 
analysis. A significant association was found between negative 
immunohistochemistry expression of ERCC1 and the platinum 
response (7 patients in the cisplatin-resistant group showed 
negative staining vs 31 patients in the cisplatin responders 
group, 12.5 vs 87.5 % respectively, p=0.001) (Fig. 2).
The analysis of ERCC1 mRNA by qPCR showed low 
ERCC1 expression in 24 cases (50%) and 17 cases showed a high 
ERCC1 expression. Among low expression cases, there were 27 
patients considered cisplatin responders (70.8%). In contrast, 
among the 30 non-cisplatin responder patients, 10 patients (41%) 
had high ERCC1 expression. There was a correlation between 
low expression of ERCC1 and cisplatin response that did not 
reach statistical significance (p=0.54) (data not shown).
Table I. Base characteristics of the patients.
Characteristics of the patients Number (%)
Age (years) 62
Range 43-81
Gender
 Male 66 (86)
 Female 10 (14)
Stage
 Limited 27   (35)
 Disseminated 49   (65)
First line chemotherapy 76 (100)
 Platinum/etoposide 76 (100)
Second line chemotherapy 49 (64.7)
 Cisplatin/adriamycin/vincristine 25 (31.5)
 Paclitaxel 16 (21)
 Topotecan   8 (10)
Third line chemotherapy 15 (19.7)
 Paclitaxel   5   (6.5)
 Topotecan   9 (11.8)
 Gemcitabine-vinorelbine   1   (1.3)
Treatment modality in limited stage 27 (35)
 Concomitant chemo-radiation 22 (28.9)
 Sequential chemo-radiation   1   (1.3)
 Chemotherapy alone   4   (5.2)
Figure 1. Positive inmunohistochemical expression of ERCC1 in a small cell 
lung cancer sample.
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TOP I expression and cisplatin response. Only 48 cases could 
be evaluated for the PCR analysis because of problems of avail-
ability of the samples. We observed an opposite relationship 
between TOP I RNA expression levels and the response to 
cisplatin: 28/36 (77.8%) patients in the responder group showed 
a low level expression of TOP I expression, whereas 9 patients 
(75%) patients in the resistant group showed high expression of 
TOP I (p=0.02) (Fig. 3).
ERCC1 and TOP I expression and prognosis. After a median 
follow-up time of 12 months, the median PFS was 6 months 
(CI 95%, 5-6.9 months) and OS was 9 months (CI 95%, 7.4-10.6) 
(Fig. 4).
Patients with negative ERCC1 immunostaining showed a 
lower risk of PFS compared to cases with positive ERCC1 immu-
nostaining HR=0.456 (CI 95% 0.256-0.819; p=0.009) (Fig. 5a). 
In contrast, the qPCR analysis of ERCC1 did not show the risk 
of PFS, with only a trend towards a lower risk of progression 
in patients with low ERCC1 mRNA levels HR=0.641 (CI 95% 
0.35-1.15; p=0.14) (Fig. 5b).
Patients with low TOP I mRNA expression showed a 
significantly lower risk of progression compared to those 
patients with high TOP I expression HR=0.446 (CI 95% 
0.223-0.888; p=0.02) (Fig. 5c).
We also analyzed for a possible correlation between TOP I 
and ERCC1 expression using Pearson correlation, but we 
could not demostrate an association (Sq r lineal = 0.036). The 
results of the univariate analysis are shown in Table II. A multi-
variate analysis was performed including gender, stage, cisplatin 
response, ERCC1 and TOP I expression. Response to cisplatin 
Figure 2. Correlation between ERCC1 inmunoexpression and cisplatin 
response.
Figure 3. Correlation between cisplatin response and mRNA expression of 
ERCC1.
Figure 4. Kaplan Meyer overall survival curve.
Table II. Univariate analysis of progresion-free survival (PFS).
Variable P-value
Stage 0.09
 Limited 
 Extensive
Gender 0.96
 Male
 Female
Response to cisplatin based-chemotherapy 0.0001a
 Positive 
 Negative
ERCC1 inmunoexpression 0.009a
 Low 
 High
ERCC1 mRNA expression 0.14
 Low 
 High
TOP I mRNA  expression 0.002a
 Low 
 High
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as well as TOP I expression were the parameters with the most 
relevant impact on survival. Cisplatin response reached statistical 
significance in the multivariate analysis (p=0.003) but TOP I 
expression showed only a trend with a statistical significance in 
the first case I expression (p=0.06) (data not shown).
Discussion
In this study, we explored the relationship between ERCC1 and 
TOP I expression and cisplatin-response and PFS in patients 
diagnosed with SCLC. ERCC1 status has been related to cispl-
atin response in other tumors such as NSCLC (22-24), bladder 
cancer (25) and head and neck cancer (26,27). However, scarce 
data have been reported with regard to SCLC, which represents 
one of the most aggressive cancer types. Moreover, SCLC 
therapy has not experienced significant improvements despite 
active research in this field in recent years. Several reports have 
demonstrated that alterations in DNA damage repair proteins 
are associated with resistance to cisplatin based chemotherapy 
or radiotherapy (25-27). Cisplatin resistance is one of the most 
important causes of treatment failure in SCLC (28). In this study 
we analyzed ERCC1 expression in relation to cisplatin response. 
This potential relationship could help us to select those patients 
with a potential cisplatin response and those with primary 
resistance. In these resistant cases, cisplatin administration could 
be avoided; decreasing associated platinum toxicity in patients 
with a positive ERCC1 expression. Our group showed a highly 
significant relationship between ERCC1 expression and cisplatin 
resistance as analyzed by IHC (p=0.001). These findings have 
a direct influence on survival: patients with ERCC1 positive 
staining had a significant worse PSF compared to those patients 
with negative staining (p=0.009). Moreover, when ERCC1 was 
analyzed by QPCR, it did not reach statistical significance. One 
possible explanation for this discordance could be the insufficient 
sample size or the lack of linear correlation between mRNA and 
protein expression. In this sense, our study is the first to compare 
ERCC1 expression both by QPCR and immunohistochemistry 
and the results point to immunohistochemistry as the method of 
choice for analysis of ERCC1.
There are two published studies that have analyzed ERCC1 
expression and PFS in SCLC (15,16). Lee et al analyzed ERCC1 
immunoexpression in tumor specimens from 77 patients with 
SCLC who were treated with a platinum regimen. The authors 
found that in LD patients, high expression of ERCC1 was an 
independent prognostic factor for poor OS (p= 0.046), along 
with male gender (p=0.033) (15). Along the same lines, Ceppi 
et al analyzed ERCC1 RNA expression in 85 patients, also 
showing that ERCC1 was an independent prognostic factor 
for survival in LD patients; however these results could not be 
reproduced in ED (16). Consistent with the two previous studies, 
we have shown that tumor stage and ERCC1 immunoexpression 
were the only variables with significant impact on PFS, p=0.04 
and 0.006, respectively. In contrast to the results of Ceppi et al, 
neither gender nor stage could be analyzed in our study due to 
the unbalanced sample size. This could also be the reason why 
the stage did not reach the statistical significance in univariate 
analysis.
Apart from ERCC1, in this report TOP I expression was 
also explored. An interesting relationship between low TOP I 
RNA expression and a better cisplatin response and PFS was 
found. The multivariate analysis showed that TOP I expression 
had a significant influence on PFS, as well as cisplatin response, 
but in the first case the association did not reach statistical 
significance. There is no previous evidence regarding the 
role of TOP I in survival nor in cisplatin prediction in SCLC. 
However, there is controversy regarding the prognosis value 
of TOP I in other types of tumors (29-33). Tsavaris et al found 
that levels of expression of TOP I were higher in malignant 
cells from tumor recurrences compared to primary tumors, 
suggesting a role of TOP I in tumor recurrence (34), but these 
Figure 5. (a) Correlation between ERCC1 inmunostaining and PFS. 
(b) Association of PFS and mRNA ERCC1 levels. (c) Correlation of mRNA 
TOP I levels and PFS.
  a
  b
  c
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results could not be confirmed by Paradiso et al (35). TOP 
I is the target of topotecan and irinotecan, which have been 
explored mainly as second line treatments, and recently, in a 
first line setting (32). Our study is the first to demonstrate a 
positive relationship between low levels of TOP I and better 
cisplatin response as well as a longer PFS in SCLC patients. 
TOP I plays a crucial function in DNA replication (36-39). 
Low levels of TOP I indicate inappropriate DNA replication, 
therefore, a lower rate of proliferation. Perhaps a high level 
of TOP I is a surrogate marker of proliferation and could be 
a prognostic factor as well as a predictive marker to response 
to chemotherapy, in this case, to cisplatin. A recent study by 
Kohara et al demonstrated in preclinical data, responses to 
TOP I inhibitors in platinum-resistant cells (40). In this study, 
we were not able to analyze the relationship between TOP I 
expression and topotecan or irinotecan treatment because only 
10% of the patients received topotecan as second line treat-
ment, and none received topotecan as first line treatment. The 
reason is that at the beginning of recruitment, topotecan was 
not yet approved for SCLC treatment in Spain. Further studies 
will be developed to explore a potential relationship between 
TOP I expression and response with contradictory results (37). 
Maden et al found that higher levels of TOP I correlated with 
sensitivity to TOP I inhibitors (38); however on the other hand, 
MacLeod et al reported that gene copy number and protein 
expression are inversely correlated with sensitivity to SN 38, 
an inroinotecan metabolite, in vitro in several breast and colon 
tumor cell lines (39).
Based on our results, we suggest that there is a positive 
impact of the low levels of TOP I mRNA on PFS, but these 
findings should be confirmed in further studies. We identified 
a profile of patients with SCLC with negative ERCC1 immu-
nostaining as well as low mRNA levels of TOP I with a good 
cisplatin response as well as a longer PSF. Mukai et al reported 
similar results in different tumors using immunohistochemistry 
and PCR analysis in tissue specimens of breast, gastric and non-
small cell lung cancer. They found that high levels of ERCC1 
and TOP I mRNA are related to recurrence (37).
In addition to this prognostic information, our results could 
be the first step in designing other studies with a large patient 
sample sizes to validate these findings. They may suggest a 
therapeutic algorithm for first line treatment based on ERCC1 
and TOP I mRNA expression/levels. Those patients with 
poor ERCC1 expression and low levels of mRNA of ERCC1 
could be treated with a platinum regimen. However, if ERCC1 
immunohistochemistry is positive or mRNA levels are high, 
cisplatin resistance is indicated, and in these cases we could 
analyze TOP I levels. According to previously reported data, 
high levels of TOP I may be involved in TOP I inhibitors 
(topotecan and irinotecan) response, but low levels would 
be associated with a poor response. In this study, it was not 
possible to report a correlation with TOP I inhibitor treatment, 
therefore, we are working on further studies to explore this 
aspect.
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